Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Lydia Wang-Lakshman, Anisha E. Mendonza, Roland Huber, Markus Walles, YanLing He & Venkateswar Jarugula. (2021) Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans. Xenobiotica 51:4, pages 413-426.
Read now
Read now
Yukihiro Chino, Masatoshi Hasegawa, Yoshiki Fukasawa, Yoko Mano, Kagumi Bando, Atsunori Miyata, Yasuhiro Nakai, Hiromi Endo & Jun-ichi Yamaguchi. (2017) In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor. Xenobiotica 47:4, pages 314-323.
Read now
Read now
Kalliopi Pafili, Efstratios Maltezos & Nikolaos Papanas. (2016) Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 12:11, pages 1367-1380.
Read now
Read now
K. Pafili, E. Maltezos & N. Papanas. (2016) The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes. Expert Opinion on Investigational Drugs 25:10, pages 1133-1152.
Read now
Read now
Mizuki Yamane, Kosuke Kawashima, Koji Yamaguchi, Shunsuke Nagao, Mika Sato, Masayuki Suzuki, Kiyofumi Honda, Hitoshi Hagita, Olaf Kuhlmann, Agnes Poirier, Stephen Fowler, Christoph Funk, Sandrine Simon, Yoshinori Aso, Sachiya Ikeda & Masaki Ishigai. (2015) In vitro profiling of the metabolism and drug–drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP. Xenobiotica 45:3, pages 230-238.
Read now
Read now
Articles from other publishers (9)
Magdalena Złotek, Antonina Kurowska, Mariola Herbet & Iwona Piątkowska-Chmiel. (2023) GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy. Biomedicines 11:11, pages 3035.
Crossref
Crossref
Anna Gumieniczek & Anna Berecka-Rycerz. (2023) Metabolism and Chemical Degradation of New Antidiabetic Drugs: A Review of Analytical Approaches for Analysis of Glutides and Gliflozins. Biomedicines 11:8, pages 2127.
Crossref
Crossref
Simon G. Wong & Shuguang Ma. 2023. Overcoming Obstacles in Drug Discovery and Development. Overcoming Obstacles in Drug Discovery and Development
137
174
.
Haruki Yamada, Hiromasa Ohira, Fumiaki Ikegami, Koichi Nakamura, Atsushi Takahashi, Kazumichi Abe, Akihiro Inano, Sumire Shimada, Kumiko Miyata, Tomohisa Saito, Yasuhiro Ohba, Kimio Terao & Akihiro Ohnishi. (2020) Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of
Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2)
Inhibitor. Drug Research 70:09, pages 401-409.
Crossref
Crossref
M. Ruscica, L. Baldessin, D. Boccia, G. Racagni & N. Mitro. (2017) Non-insulin anti-diabetic drugs: An update on pharmacological interactions. Pharmacological Research 115, pages 14-24.
Crossref
Crossref
Shinji Kobuchi, Megumi Matsuno, Etsuko Fukuda, Yukako Ito & Toshiyuki Sakaeda. (2016) Development and validation of an LC–MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats. Journal of Chromatography B 1027, pages 227-233.
Crossref
Crossref
André J. Scheen. (2015) Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clinical Pharmacokinetics 54:7, pages 691-708.
Crossref
Crossref
Oleg Demin, Tatiana Yakovleva, Dmitry Kolobkov & Oleg Demin. (2014) Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model. Frontiers in Pharmacology 5.
Crossref
Crossref
Raewyn M. Poole & Jennifer E. Prossler. (2014) Tofogliflozin: First Global Approval. Drugs 74:8, pages 939-944.
Crossref
Crossref